According to new research published online Monday at the Journal of Clinical Oncology, 63% of the patients taking the immunotherapy were alive after one year and 43% were still alive after two years on the drug. And the researchers say that the durable response was also reflected in patients who had stopped taking the drug.
Is Pfizer and Bristol-Myers Squibb's Eliquis really safer than its competitors? A recent analysis of FDA adverse events reports suggested that it is.
Bristol-Myers Squibb has picked up its second "breakthrough" drug designation for a daclatasvir-based, all-oral combo for hepatitis C from the FDA, potentially shaving some regulatory time off its late-stage program as developers scramble to hijack market share from Gilead's pioneering approach.
Government officials in France have been known to scream loudly when drugmakers have planned job-costing moves like plant closures. But in a twist on that theme, Bristol-Myers Squibb has sent French government officials a warning. If they change the national health policy to buy only generic paracetamol-based painkillers, it will have to lay off 40% of the workers at two plants in Agen that make its branded versions of the drugs.
In the biotech and pharma industries, drug delivery is a crucial aspect of research and development. Finding new ways to deliver old drugs, ways to make a new drug more efficient or ways that make a...
The National Institutes of Health has persuaded 10 rival drugmakers to briefly set aside their competitive spirits and collaborate on drug discovery projects in four major diseases, pooling their data and expertise to kick-start early-stage efforts.
Bristol-Myers Squibb says its Eliquis DTC campaign is doing its part to help get sales where the company wants them. Revenues for the anticoagulant may not be where many analysts expected they'd be when they talked the drug up as a future $3-billion-a-year blockbuster. But they are on the rise--thanks, in part, to the campaign, launched in September. And BMS says it's not stopping there.
When BMS said it would continue its mid-stage instead of diving into a late-stage program testing nivolumab with melanoma hit Yervoy, investors feared it could mean problems with the combo--and sent shares down nearly 6%.
Bristol-Myers Squibb's got some pumped-up sales to go along with its slimmed-down focus. In the fourth quarter, revenue increases and decreased costs helped the company beat Wall Street's earnings estimates on the way to zeroing in on its new-look pharma model.
Bristol-Myers Squibb says it's on the lookout for new deals, but that its focus will be on snapping up experimental treatments still in development instead of commercial products already on the market, according to a Bloomberg story.